Compare Global E Online Ltd (GLBE) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Johnson & Johnson — how do they compare? Global E Online Ltd trades at $40.44 (market cap $6.87B), while Johnson & Johnson trades at $260.51 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 91.1× Global E Online Ltd's market cap, and Johnson & Johnson pays a 2.06% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals.
| GLBE | JNJ | |
|---|---|---|
Market Cap | $6.87B | $626.09B |
Sector | Technology | Health |
52-Week High | $42.32 | $267.24 |
52-Week Low | $27.54 | $172.78 |
Enterprise Value | $6.34B | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $40.55, down 1.46% on the day, with a bullish technical outlook supported by moving averages and strong institutional support. The company reported Q2 2026 earnings that beat expectations with revenue growth of 39% YoY and raised full-year guidance. Analyst consensus remains unanimously bullish with a $44.75 price target representing 10.4% upside potential.
GLBE demonstrates strong fundamental momentum with expanding profit margins and robust revenue growth, though elevated valuation multiples present near-term risk. The Passport acquisition enhances logistics capabilities while insider selling activity warrants monitoring. The stock offers growth exposure but requires careful risk management given premium valuations.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
